A new type of CB1 drug reduces THC withdrawal symptoms in mice | Research

The takeaway

A CB1 positive allosteric modulator (ZCZ011) significantly reduced physical signs of THC withdrawal in mice without causing the sedation or psychoactive effects typical of direct CB1 activators.

Researchers studying cannabis dependence and pharmacologists interested in allosteric modulation.

Reduced withdrawal without sedation or reward

What the researchers found

ZCZ011 (at 10 mg/kg and above) significantly reduced somatic withdrawal signs including head twitches and paw tremors in both precipitated and spontaneous THC withdrawal models. Importantly, ZCZ011 did not affect locomotor activity and did not produce conditioned place preference, suggesting it lacks the rewarding and sedating properties of direct CB1 agonists.

Why it matters

Cannabis withdrawal is increasingly recognized as a clinical problem. A drug that eases withdrawal without producing its own psychoactive effects or abuse potential could be a useful treatment tool.

The numbers in context

THC dose: 10 mg/kg. ZCZ011 effective at 10 mg/kg and above. Rimonabant precipitating dose: 3 mg/kg. ZCZ011 also blocked NSAID-induced gastric ulcers when combined with 1 mg/kg JZL184.

How the study worked

Mice were repeatedly administered THC (10 mg/kg) then withdrawal was either precipitated with rimonabant or allowed to occur spontaneously via THC abstinence. ZCZ011 was tested at multiple doses. Additional experiments tested ZCZ011 for anti-ulcer properties.

What this study cannot tell us

Animal study only (mice). Effects may not translate to humans. THC withdrawal in mice presents differently than in humans. No cognitive outcomes measured.

How to read the evidence

Well-designed animal study with multiple experimental models, but no human data.

When this study was published

2019 preclinical study.

The bigger picture

Allosteric modulators represent a newer pharmacological approach that fine-tunes receptor activity rather than fully activating or blocking it, potentially offering better safety profiles for cannabinoid-based treatments.

Questions still open

Would CB1 positive allosteric modulators reduce withdrawal symptoms in humans? Could this approach also help manage tolerance to medical cannabis?

Common questions

Is there a medication for cannabis withdrawal?

Not yet approved for humans, but this animal study showed a CB1 positive allosteric modulator reduced physical withdrawal signs in mice without causing sedation or its own abuse potential.

What is an allosteric modulator?

Rather than directly activating or blocking a receptor, an allosteric modulator binds to a different site and fine-tunes how the receptor responds to its natural signals, potentially offering more targeted effects with fewer side effects.

Read the original research

CB1 positive allosteric modulation attenuates Δ9-THC withdrawal and NSAID-induced gastric inflammation.

Pharmacology, biochemistry, and behavior, 177, 27-33

View on PubMed ↗Publisher’s paper ↗

Citation

Trexler, K R; Eckard, M L; Kinsey, S G. (2019). CB1 positive allosteric modulation attenuates Δ9-THC withdrawal and NSAID-induced gastric inflammation.. Pharmacology, biochemistry, and behavior, 177, 27-33. https://doi.org/10.1016/j.pbb.2018.12.009